Literature DB >> 21771130

How prompt is prompt in daily practice? Earlier initiation of empirical antibacterial therapy for the febrile neutropenic patient.

M van Vliet1, C M J Potting, P D J Sturm, J P Donnelly, N M A Blijlevens.   

Abstract

With fever being the most common manifestation of early sepsis, clinical practice guidelines emphasise the prompt institution of broad-spectrum antibacterial therapy at its onset. An audit was performed on the haematology ward to determine whether there was any delay in starting antibiotic treatment during neutropenia in clinical patients and to define the main reasons for this. Strategies were developed, implemented and evaluated on short- and long-term implications on the delay in the start of antibacterial therapy. The procedures specified in the protocol for starting empirical antibacterial therapy were audited to assess whether the target for starting therapy within 30 min of fever was achieved. Initial results indicated that two major changes to the protocol were necessary to achieve a reduction in the delay between detection of fever and starting antibacterial therapy. This modified protocol was evaluated 4 months after implementation by means of a consecutive audit. After 3 years, a third audit was performed to determine the long-term implications of the improved protocol. In the initial audit, the mean time interval between the onset of fever and the administration of antibacterial therapy was 75 min. With the modified protocol, the mean time to starting therapy was shortened to 32 min (P < 0.05). Changing the protocol for starting antibacterial therapy allowed nurses to administer the first dose of antibiotic significantly earlier.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771130     DOI: 10.1111/j.1365-2354.2011.01264.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  5 in total

1.  Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia.

Authors:  Regis G Rosa; Luciano Z Goldani
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

2.  Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review.

Authors:  Christa Koenig; Christine Schneider; Jessica E Morgan; Roland A Ammann; Lillian Sung; Bob Phillips
Journal:  Support Care Cancer       Date:  2019-07-01       Impact factor: 3.603

3.  Symptom to door interval in febrile neutropenia: perspective in India.

Authors:  Sapna Oberoi; Amita Trehan; R K Marwaha; Deepak Bansal
Journal:  Support Care Cancer       Date:  2012-12-15       Impact factor: 3.603

4.  Time to antibiotic administration in children with febrile neutropenia: Report from a low middle-income country.

Authors:  Namrata Todurkar; Amita Trehan; Deepak Bansal
Journal:  Indian J Med Res       Date:  2021-04       Impact factor: 5.274

Review 5.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer
Journal:  Ann Hematol       Date:  2017-08-30       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.